NasdaqGM:HELPPharmaceuticals
Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds
Cybin (HELP) is drawing fresh attention after reporting that enrollment in its APPROACH Phase 3 trial for HLP003 in major depressive disorder has surpassed 86%, a key marker in its broader PARADIGM program.
See our latest analysis for Cybin.
The recent APPROACH trial update comes after a sharp short term rebound in Cybin's 1 week and 1 month share price returns of 38.76% and 42.42% respectively. This is set against a year to date share price return that is still down 21.74% and a 5 year total...